Purified protein derivative test and its booster phenomenon in patients with rheumatoid arthritis


1 Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Community Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Rheumatoid arthritis (RA) is a common disease in the community, with various complications. An appropriate solution is immunosuppressive drugs, which may lead to weakening of the cellular immune system and body unresponsiveness to tuberculosis (TB). As TB sensitivity is determined by the amount of induration created in the Purified Protein Derivative (PPD) test, this study aims to evaluate the immune response to the PPD test and its booster in RA patients.
Materials and Methods: This cross-sectional study was performed on rheumatoid arthritis patients referred to Alzahra Hospital, Isfahan, treated with ‹20 mg glucocorticoid daily or 7.5 mg Methotrexate (MTX) weekly. The sampling method was simple and accessible. The PPD test was performed in patients using the Mantoux method after 72 hours, and seven days later, the results were interpreted in 72 hours after the PPD booster injection. Induration ≥5 mm was considered to be positive. The data was analyzed using the SPSS software.
Results: Nineteen patients had positive results in the initial and reminder tests and 81 patients had negative results in both tests. Six patients (6.9%) with negative results in the initial test changed to positive in the reminder test. There was no positive result in the initial test and negative result in the reminder one. The frequency distribution of the reminder test, based on the initial test was significant (P < 0.001). Also, the McNemar test showed that the changes in the reminder test based on the initial test had a significant difference (P = 0.031).
Conclusion: It seems that in the endemic and developing areas, the PPD booster is applicable for diagnosing latent tuberculosis in patients with rheumatoid arthritis.


Nizam S, Emery P. Attenuated response to purified protein derivative in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:980.  Back to cited text no. 1
Köker IH, Pamuk ON, Karlikaya C, Tunçbilek N, Cakir N. A low prevalance of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings. Clin Exp Rheumatol 2007;25:54-9.  Back to cited text no. 2
Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 2007;34:474-80.  Back to cited text no. 3
Sezer I, Kocabas H, Melikoglu MA, Arman M. Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. Clin Rheumatol 2009;28:53-7.   Back to cited text no. 4
Ahanjan M, Nasrollahi M. Evaluation of tuberculin test (ppd) in street cleanser of sari's tawn. J Mazandaran Med Sch 1996;27:40-3.  Back to cited text no. 5
Ponce de LD, Acevedo VE, Sánchez TA, Cucho M, Alfaro J, Perich R, et al.. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.  Back to cited text no. 6
Modarres B. Review of rheumatologic from laboratory point of view. Available from: http://www.drmodarreslab.ir/index.php [Last accessed on 2013 July 7].  Back to cited text no. 7
Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al.. Screening for latent tuberculosis infection: Performance of tuberculin skin test and interferon-release assays under real-life conditions. Ann Rheum Dis 2012;71:1791-5.  Back to cited text no. 8
Meidani M, Mortazawi Najafabadi M, Emami Naeeni A, Khorvash F, Rezaie N. Booster Phenomenon of 3-Step Tuberculin SkinTesting in Hemodialysis Patients. Isfahan Med Sch 2011;116:1049-55.  Back to cited text no. 9